In 2011, Taiho Pharmaceutical established Taiho Pharma Singapore Pte. Ltd. as a development and marketing base in Southeast Asia. The new company is marketing the anticancer agents TS-1 (known as TS-ONE locally), LONSURF, UFT and Futraful either independently or through business partners.

Sticking with its philosophy, “by local, for local,” Taiho Pharma Singapore Pte. Ltd. covers a wide range of jobs such as regulatory affairs, medical affairs and sales of anticancer drugs as a hub for Taiho’s oncology business in Southeast Asia in close touch with local medical oncologists and the other medical professionals in cancer care.

Our goal at Taiho is to protect and nurture human lives, and we never forget that all lives are irreplaceable and precious. Our focus as we pioneer and produce our line of specialty pharmaceuticals is not the drug industry, but the benefit of the people we serve.